Latest Content

How shifting cannabis laws shape potency, access, and risk—revealing why anxiety, paranoia, and psychosis can surge when users cross regulatory borders.

Learn how fast-acting oral zuranolone treats postpartum depression in days, with practical prescribing and breastfeeding guidance clinicians can use.

FDA accepts AXS-12 NDA for cataplexy in narcolepsy after phase 3 shows fewer attacks, better wakefulness, and cognition; decision due May 2027.

Explore how dopamine D2 blockade shapes antipsychotic benefits and risks, revealing dosing pitfalls, polypharmacy harms, and why plasma level monitoring improves outcomes.

A psychiatric clinician reveals how peers can spark small daily joy, beat burnout, and build balanced wellness that lasts.

New treatments, responsible deprescribing, and encouraging 988 gains reshape US mental health on our 250th anniversary.

AI chatbots flood mental health care—convenient and validating, yet risky. Learn where they help, where they harm, and why therapists still matter.

New primate data show IV tau-silencing gene therapy cuts brain tau up to 75% with liver-sparing safety, clearing path for 2026 trial.

A panel of expert psychiatrists define deprescribing as ongoing medication review, guiding safer, personalized psychopharmacology amid polypharmacy, misdiagnosis, and fragmented care.

At the Southern California Psychiatry Conference, Jason Kellogg, MD, shares insights into the evolution of the MDD pipeline, with an eye on rapid-acting novel mechanisms.

AI is reshaping psychopharmacology—from TRD prediction to digital phenotyping—while exposing data limits, workflow hurdles, and safety risks in suicide tools.

Experts explain why every diagnosis needs metabolic screening, how to discuss risk safely, and when to use tools like PsyMetRiC to assess risk.

Psychiatrists unpack parental leave anxiety, FMLA gaps, and how smarter time-off planning can reduce postpartum depression and support working families.